Close Menu
    Facebook X (Twitter) Instagram
    Trending
    • Experience Everyday Comfort with Voltas Water Heaters
    • Messi Inspires Argentina’s Stunning Comeback Against Egypt
    • Rupee Ends Lower At 95.38 Against U.S. Dollar
    • U.S. Strikes Iran After Hormuz Ship Attacks
    • What To Expect From The 2026 NATO Summit In Turkey
    • Gadkari Defends E20 Fuel, Challenges Critics
    • SC To Hear Plea Against Vijay’s Visit To Karur Victims
    • ZEE5 Urges Fans To Avoid Piracy After Satluj Removal
    Facebook X (Twitter) YouTube
    Khabar India
    Khabar India Banner
    • Media Monitoring
    • National
    • ENTERTAINMENT
    • UP/STATES
    • BUSINESS
    • SPORTS
    • CRIME
    • INTERNATIONAL
    • EDUCATION
    Khabar India
    You are at:Home » Coronavirus Updates: Positive Cases In India Cross 4.25-Lakh Mark

    Coronavirus Updates: Positive Cases In India Cross 4.25-Lakh Mark

    0
    By Aruna Sharma on June 22, 2020 National

    (FE)

    With the number of coronavirus cases crossing the 4 lakh-mark, India is now ranked fourth after United States, Brazil and Russia in the list of worst-affected countries by the COVID-19 disease. According to WHO, Sunday witnessed the highest-ever single day spike in cases. Worldwide, more than 183,000 new cases in the latest 24 hours. As per the health ministry’s latest data on Monday, 445 deaths and spike of 14,821 new COVID-19 positive cases were reported in India in last 24 hours. Coronavirus positive cases in India stand at 4,25,282 including 1,74,387 active cases, 2,37,196 cured/discharged/migrated. The death toll is 13,699, the ministry said. However, there is one silver lining that the recovery rate from the disease has now touched 55%. Maharashtra, Delhi, Tamil Nadu, Gujarat and Uttar Pradesh are among the states reporting most number of coronavirus cases in India.

    Meanwhile, in what could be seen as a big achievement in the fight against the global pandemic, Indian pharmaceutical company Glenmark has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of Coronavirus. The Mumbai headquartered company said the medicine, which is priced at Rs 103 per tablet, can be used to treat mild to moderate COVID-19 cases.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Aruna Sharma

    Related Posts

    Experience Everyday Comfort with Voltas Water Heaters

    FIFA World Cup: Portugal Face Spain in Round of 16 as Quarter-final Line-up Takes Shape

    Celina Jaitly to Play Sister Nivedita in Ram Kamal Mukherjee’s Biographical Drama

    • Facebook 99K
    • Twitter 1.5K
    • YouTube 370
    • Popular
    • Video
    • Pvt Sector
    July 24, 2026

    Experience Everyday Comfort with Voltas Water Heaters

    July 8, 2026

    Messi Inspires Argentina’s Stunning Comeback Against Egypt

    July 8, 2026

    Rupee Ends Lower At 95.38 Against U.S. Dollar

    July 23, 2025

    PM Narendra Modi Interacts With Media On The First Day Of Monsoon Session Of Parliament

    February 11, 2025

    Prime Minister Narendra Modi Gets A Rousing Welcome By Indian Community In Paris, France

    February 11, 2025

    Prime Minister Narendra Modi Attends Dinner Hosted By French President In Paris

    July 8, 2026

    Messi Inspires Argentina’s Stunning Comeback Against Egypt

    July 8, 2026

    Mbappé Slams Racist Remarks By Paraguayan Senator

    July 7, 2026

    Ronaldo’s World Cup Dream Ends

    Company
    Company
    Recent Posts
    • Experience Everyday Comfort with Voltas Water Heaters
    • Messi Inspires Argentina’s Stunning Comeback Against Egypt
    • Rupee Ends Lower At 95.38 Against U.S. Dollar
    • U.S. Strikes Iran After Hormuz Ship Attacks
    • What To Expect From The 2026 NATO Summit In Turkey
    • Media Monitoring
    • National
    • ENTERTAINMENT
    • UP/STATES
    • BUSINESS
    • SPORTS
    • CRIME
    • INTERNATIONAL
    • EDUCATION
    Copyright © 2017 khabarindia.in. About / Privacy Policy / Terms and Condition / Contact Us

    Type above and press Enter to search. Press Esc to cancel.